Improving outcome in schizophrenia: The potential importance of EPS and neuroleptic dysphoria

Annals of Clinical Psychiatry

Volumn 14, Issue 1, 2002, Pages 47-57

  Gerlach, Jes ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Atypical antipsychotics; Compliance; EPS; Neuroleptic dysphoria; Outcome; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; AKINESIA; ARTICLE; DISTRESS SYNDROME; DYSPHORIA; DYSTONIA; ECONOMIC ASPECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; TREMOR; AFFECT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; EXTRAPYRAMIDAL SYSTEM; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; REVIEW;

AFFECT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; EXTRAPYRAMIDAL TRACTS; HUMAN; PATIENT COMPLIANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; HUMANS;

EID: 0036001464     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015276028425     Document Type: Article

References (69)

1. Follow-up studies of schizophrenia. I: Natural history and non-psychopathological predictors of outcome
2. Optimising prophylactic treatment of schizophrenia by means of treatment standards and compliance improvement
3. Results of treatment of schizophrenia: Is the glass half full or half empty?
4. Twenty years' follow-up of first psychiatric presentation for schizophrenia: What could have been prevented?
5. The content and context of compliance
6. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
7. Frequent rehospitalization and noncompliance with treatment
8. Rehospitalization in chronic schizophrenia
9. From noncompliance to collaboration in the treatment of schizophrenia
10. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
11. Compliance in psychoses
12. Subjective response to neuroleptics and the quality of life: Implications for treatment outcome
13. Which side-effects really matter to our patients?
14. The St. Hans Rating Scale for extrapyramidal syndromes: Reliability and validity
15. Compliance and outcome in patients treated with antipsychotics. The impact of extrapyramidal syndromes
16. Antipsychotic drug-induced dysphoria
17. Dysphoric phenomena associated with haloperidol treatment of Tourette syndrome
18. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics
19. Subjective utility ratings of neuroleptics in treating schizophrenia
20. Why do schizophrenic patients refuse to take their drugs?
21. A two-year prospective study of treatment compliance in patients with schizophrenia
22. Compliance with antipsychotic drug treatment: Influence of side effects
23. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight
24. Is neuroleptic dysphoria a healthy response?
25. Response to antipsychotic medication: The doctor's and the consumer's view
26. Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance
27. Treatment of neuroleptic-resistant schizophrenic relapse
28. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment
29. Correlations between akathisia and residual psychopathology: A by-product of neuroleptic-induced dysphoria
30. Subjective response to antipsychotic drugs
31. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point
32. Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey
33. The costs of schizophrenia. Assessing the burden
34. The economic impact of schizophrenia
35. Economics and schizophrenia: The real cost
36. The economic burden of schizophrenia in Canada
37. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis
38. The economic burden of schizophrenia
39. Cost of relapse in schizophrenia
40. Spontaneous and drug-induced movement disorders in schizophrenia
41. Assessment and management of antipsychotic-induced adverse events
42. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States
43. New atypical antipsychotic medications
44. Extrapyramidal side effects and tolerability of risperidone: A review
45. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
46. Olanzapine: An updated review of its use in the management of schizophrenia
47. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
48. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
49. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
50. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
51. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study
52. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia
53. Patient satisfaction and acceptability of long-term treatment with quetiapine
54. Treatment of special populations with the atypical antipsychotics
55. Pharmacological management of schizophrenia in older patients
56. Treatment of schizophrenia and delusional disorder in the elderly
57. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication
58. The treatment of psychosis in late life
59. The older patient: The ongoing challenge of efficacy and tolerability
60. Managing antipsychoticinduced parkinsonism
61. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
62. Paediatric psychopharmacology: Closing the gap between science and practice
63. Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms
64. Predictors of acute dystonia in first-episode psychotic patients
65. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy
66. Neuronal damage of the substantia nigra in HIV-1 infected brains
67. Long-term use of quetiapine in elderly patients with psychotic disorders
68. Safety, tolerability and clinical effectiveness of quetiapine in adolescents with selected psychotic disorders: A long-term, open-label study